TWiPO #82: Dr. Brenda Weigel on The RACE Act & Early Phase Clinical Trials
Play • 32 min

Host Tim Cripe welcomes his new Co-Host, Dr. Brenda Weigel, to reflect on her career, leadership, and focus areas since her last interview on TWiPO in 2017. Dr. Weigel is the Director of the Division of Pediatric Hematology/Oncology at the University of Minnesota's Cancer Center, Chair of Developmental Therapeutics in the COG, and Chair of the Pediatric Early Phase Clinical Trials Network (PEP-CTN) for the NCI.

 

She is at the epi-center for getting new drugs into the clinic for children with cancer and shares her perspective on the impact of the game-changing RACE Act that was implemented in 2020. She weighs in on prioritization of same-class drugs, evolving clinical trial design for small patient populations, and the increasing need for international collaboration in conducting clinical trials. She also discusses the importance of quality-of-life assessments and patient-reported outcomes and shares the efforts ongoing in the US and EU regulatory landscape to advance drug development for children with cancer.

More episodes
Search
Clear search
Close search
Google apps
Main menu